Minerva Neurosciences

Focused on developing innovative therapies to treat central nervous system disorders

Minerva’s goal is to transform the lives of patients with improved therapeutic options. The company’s portfolio of compounds includes: roluperidone (MIN-101), in clinical development for schizophrenia; a potential royalty stream from seltorexant (MIN-202 or JNJ-42847922), in clinical development for insomnia and major depressive disorder (MDD); and MIN-301, in pre-clinical development for Parkinson’s disease.

Status
NASDAQ: NERV
Year of Investment
2020
Strategy
Life Sciences
Location
Waltham, Massachusetts